The estimated Net Worth of Paul Parkinson is at least $2.31 Million dollars as of 8 January 2021. Mr Parkinson owns over 11,824 units of Myriad Genetics stock worth over $2,016,885 and over the last 4 years he sold MYGN stock worth over $295,600.
Mr has made over 1 trades of the Myriad Genetics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 11,824 units of MYGN stock worth $295,600 on 8 January 2021.
The largest trade he's ever made was selling 11,824 units of Myriad Genetics stock on 8 January 2021 worth over $295,600. On average, Mr trades about 1,971 units every 0 days since 2020. As of 8 January 2021 he still owns at least 76,746 units of Myriad Genetics stock.
You can see the complete history of Mr Parkinson stock trades at the bottom of the page.
Paul Chip Parkinson is the Exec. VP of Reimbursement Strategy at Myriad Genetics.
Paul's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: